234 related articles for article (PubMed ID: 31325056)
1. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
Bi Y; Liu J; Wang J; Epps RE; Kettl D; Marcus K; Seo S; Zhu H; Wang Y
AAPS J; 2019 Jul; 21(5):91. PubMed ID: 31325056
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab: A Review in Hidradenitis Suppurativa.
Kim ES; Garnock-Jones KP; Keam SJ
Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
Nader A; Beck D; Noertersheuser P; Williams D; Mostafa N
Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
[No Abstract] [Full Text] [Related]
7. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
[TBL] [Abstract][Full Text] [Related]
8. Model-Informed Approach Supporting Approval of Adalimumab (HUMIRA) in Pediatric Patients with Ulcerative Colitis from a Regulatory Perspective.
Li RJ; Ma L; Kim H; Kim I; Hanes L; Altepeter T; Lee J; Liu J; Zhu H; Wang Y
AAPS J; 2022 Jul; 24(4):79. PubMed ID: 35790574
[TBL] [Abstract][Full Text] [Related]
9. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for the treatment of hidradenitis suppurativa.
Folkes AS; Hawatmeh FZ; Wong A; Kerdel FA
Expert Opin Emerg Drugs; 2020 Sep; 25(3):201-211. PubMed ID: 32667213
[TBL] [Abstract][Full Text] [Related]
11. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
[No Abstract] [Full Text] [Related]
12. Low-dose adalimumab biosimilar (ZRC-3197) in the treatment of hidradenitis suppurativa.
Patil S
Indian J Dermatol Venereol Leprol; 2018; 84(6):745-747. PubMed ID: 30289113
[No Abstract] [Full Text] [Related]
13. Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial.
Bechara FG; Podda M; Prens EP; Horváth B; Giamarellos-Bourboulis EJ; Alavi A; Szepietowski JC; Kirby J; Geng Z; Jean C; Jemec GBE; Zouboulis CC
JAMA Surg; 2021 Nov; 156(11):1001-1009. PubMed ID: 34406349
[TBL] [Abstract][Full Text] [Related]
14. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
[TBL] [Abstract][Full Text] [Related]
15. Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment.
Atzori L; Bonato F; Pilloni L; Rongioletti F
Dermatol Ther; 2020 Jan; 33(1):e13160. PubMed ID: 31705612
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab (Humira°) and hidradenitis suppurativa.
Prescrire Int; 2017 Apr; 26(181):94-96. PubMed ID: 30730659
[No Abstract] [Full Text] [Related]
17. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
[TBL] [Abstract][Full Text] [Related]
18. Cellulitis-like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa.
Canal Garcia E; Vargas Ramos JDP; Aguayo Ortiz R
Australas J Dermatol; 2020 Nov; 61(4):e448-e449. PubMed ID: 32567672
[No Abstract] [Full Text] [Related]
19. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
[TBL] [Abstract][Full Text] [Related]
20. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
Gunter SJ; Holcomb ZE; Lam BD; Porter ML; Kimball AB
JAMA Dermatol; 2024 Jun; 160(6):678-681. PubMed ID: 38717768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
